PEG-ENDO + carboplatin + paclitaxel

This is a combination chemotherapy regimen comprising carboplatin, paclitaxel, and a PEGylated drug delivery system, "PEG-ENDO". The carboplatin-paclitaxel combination is a well-established regimen used in various cancers. Carboplatin is an alkylating agent that cross-links DNA, while paclitaxel is a microtubule inhibitor that stabilizes microtubules, preventing depolymerization. This combination offers synergistic effects by killing cancer cells in different ways. The PEG-based delivery system, though "PEG-ENDO" itself is not specifically detailed, likely utilizes polyethylene glycol to enhance drug solubility, prolong circulation, improve tumor targeting, sustain drug release, reduce administration frequency, and decrease systemic toxicity, thereby potentially improving efficacy and reducing adverse effects compared to the unformulated drugs. Crucially, for optimal efficacy, paclitaxel must be administered before carboplatin, as carboplatin given first inhibits paclitaxel's effect. The drugs are typically administered intravenously, often with pre-medication for side effect prevention.

Other names

Carboplatin-paclitaxel with PEG-based delivery